President Donald Trump just signed an executive order that reclassified marijuana from a Schedule I narcotic to Schedule III.
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Investor's Business Daily on MSN
Eli Lilly lags in the weight-loss pill war. But it has a plan.
Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug ...
Each and every year, music fans gather to see who will land the coveted Christmas number one spot, earning themselves a spot in the history books. Some of the most iconic festive tracks have soared to ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
4d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Culturally congruent care and better understanding of the underlying causes are crucial to help achieve equitable treatment ...
On Dec. 17 the New Jersey Cannabis Regulatory Commission voted to keep the Social Equity Excise Fee stable at $2.50 per ounce ...
Zacks Investment Research on MSN
Here's how VKTX's obesity drug is moving quickly through phase III
Viking Therapeutics VKTX is one of the few companies with a late-stage obesity candidate in its pipeline. The company is ...
Impressive Black Spoon challengers also give the elite White Spoon chefs a run for their money. Read more at straitstimes.com ...
Politicians who campaigned to bring Egyptian democracy activist Alaa Abd El-Fattah to Britain are ducking for cover now that ...
Will America be able to come to terms with the Jan. 6, 2021, U.S. Capitol riot as the fifth anniversary rolls around?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback